The first participants aged six months to 11 years have been administered Pfizer’s COVID-19 vaccine as part of a global trial assessing safety and tolerability in younger age groups, the company announced Thursday.
The first participants aged six months to 11 years have been administered Pfizer’s COVID-19 vaccine as part of a global trial assessing safety and tolerability in younger age groups, the company announced Thursday.
